Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 13/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 0.98 |
| ▸ | MITF | O75030 | 3/20 | 0.81 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.81 |
| ▸ | NPC1 | O15118 | 1/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | GAA | P10253 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.74 |
| ▸ | HTT | P42858 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.72 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13148038 | 1.00 | CSF1R (1.00) | CSF1RPOLBMITFHSP90AA1NPC1 | |
| SCHEMBL13148062 | 0.90 | CSF1R (1.00) | CSF1RPOLBMITFHSP90AA1NPC1 | |
| SCHEMBL13148057 | 0.89 | CSF1R (1.00) | CSF1RPOLBMITFHSP90AA1NPC1 | |
| SCHEMBL13148031 | 0.88 | CSF1R (1.00) | CSF1RPOLBMITFHSP90AA1NPC1 | |
| SCHEMBL13180531 | 0.87 | CSF1R (1.00) | CSF1RPOLBMITFHSP90AA1NPC1 | |
| SCHEMBL13148049 | 0.85 | CSF1R (1.00) | CSF1RPOLBMITFHSP90AA1NPC1 | |
| SCHEMBL13148026 | 0.85 | CSF1R (1.00) | CSF1RPOLBMITFHSP90AA1NPC1 | |
| SCHEMBL13148021 | 0.84 | CSF1R (0.73) | CSF1RPOLBMITFHSP90AA1NPC1 | |
| SCHEMBL13148100 | 0.84 | CSF1R (0.73) | CSF1RPOLBMITFHSP90AA1NPC1 | |
| SCHEMBL13148014 | 0.83 | CSF1R (1.00) | CSF1RPOLBMITFHSP90AA1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790724-B2 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-07 | — | — | US | disclosed |
| US-7790724-B2 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-07 | — | — | US | disclosed |
| US-7429603-B2 | Such as 5-nitro-furan-2-carboxylic acid (2-piperidin-1-yl-phenyl)-amide; diabetes, angiogenesis, psoriasis, restenosis, schizophrenia, rheumatoid arthritis, cardiovascular disease, cancer | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429603-B2 | Such as 5-nitro-furan-2-carboxylic acid (2-piperidin-1-yl-phenyl)-amide; diabetes, angiogenesis, psoriasis, restenosis, schizophrenia, rheumatoid arthritis, cardiovascular disease, cancer | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429603-B2 | Such as 5-nitro-furan-2-carboxylic acid (2-piperidin-1-yl-phenyl)-amide; diabetes, angiogenesis, psoriasis, restenosis, schizophrenia, rheumatoid arthritis, cardiovascular disease, cancer | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| WO-2007123516-A1 | C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| US-20050004112-A1 | C-fms kinase inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004112-A1 | C-fms kinase inhibitors | FLT3, FGR, FER | CSF1R 76/4885POLB 4110/4885MITF 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.